Diagnostic Imaging&#x27;s Top Five Prostate Imaging Content of 2023

FDA Clears Updated MRI/Ultrasound Fusion System for Use in Focal Therapy of Prostate Cancer

An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.

Adjunctive AI Bolsters Lesion-Level PPVs for csPCa in International bpMRI Study

Advanced annotation with the updated UroNav MRI/ultrasound fusion platform may facilitate enhanced precision and efficiency with focal therapies for prostate cancer.

Study: Adjunctive AI Provides Over 18 Percent Higher Lesion-Level Sensitivity on Prostate MRI

The use of adjunctive bpMRI-based AI led to 10 percent and greater increases in lesion-level PPV for csPCa and PCa with a threshold of PI-RADS > 3.

Emerging Medication for mCRPC Gets FDA Fast Track Designation for Adjunctive Use with Radiation Therapy

Emerging research revealed significantly enhanced sensitivity for prostate cancer detection with adjunctive and stand-alone use of AI.

CMS Issues Permanent HCPCS Code for the PSMA PET Prep Modality Gozellix

Currently in a phase I trial for solid prostate cancer tumors, the deoxycytidine kinase inhibitor TRE-515 garnered the fast track designation for possible combination use with Pluvicto in treating mCRPC.

Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging

The HCPCS level II code A9616 goes into effect on October 1 for the PSMA PET preparation kit, which received FDA approval in March.

Related Content

FDA Clears Updated MRI/Ultrasound Fusion System for Use in Focal Therapy of Prostate Cancer

Adjunctive AI Bolsters Lesion-Level PPVs for csPCa in International bpMRI Study

Advanced annotation with the updated UroNav MRI/ultrasound fusion platform may facilitate enhanced precision and efficiency with focal therapies for prostate cancer.

Study: Adjunctive AI Provides Over 18 Percent Higher Lesion-Level Sensitivity on Prostate MRI

The use of adjunctive bpMRI-based AI led to 10 percent and greater increases in lesion-level PPV for csPCa and PCa with a threshold of PI-RADS > 3.

Emerging Medication for mCRPC Gets FDA Fast Track Designation for Adjunctive Use with Radiation Therapy

Emerging research revealed significantly enhanced sensitivity for prostate cancer detection with adjunctive and stand-alone use of AI.